NEWS & EVENTS
The immuno-oncology market has grown at a compound rate of 10%, from $57 billion to $69 billion in 2021. It is expected to reach around $98 billion by 2025. This is a highly competitive market, so...
January 7th, 2022 Missoula, MT Inimmune (Missoula, MT), a biotechnology company focused on devleoping the next generation of vaccines and immunotheraputics, has appointed Jon Ruckle, M.D. as Chief...
EXCERPT: Looking to build on Missoula’s reputation as a community that fosters innovative thinkers, the University of Montana and its Montana Technology Enterprise Center (MonTEC) are creating an...
Inimmune receives Small Business Innovation Research Contract to develop novel treatments targeting Allergic Rhinitis.
Inimmune Corporation, a biotechnology company located in Missoula, MT, was recently awarded $1,836,453 from the National Institute for Allergy and Infectious Diseases (NIAID) under its Small...
Inimmune Corporation, a biotechnology company located in Missoula, MT, was recently awarded Phase I Small Business Innovation Research (SBIR) award of $ 598,808 from the National Institute for...
Missoula-based Inimmune Corporation was named the Montana Ambassadors Business of the Year in an announcement this week by Governor Gianforte. This award is presented annually to a Montana business...
For Missoula’s Inimmune, a $22 M Series A Round with Two Bear Capital is the latest record set – MT High Tech Business Alliance
Look for us at these upcoming conferences. If you are interested in scheduling a face to face meeting during one of these conferences please use the contact button
BIO International – June 2020
Smith AJ, Li Y, Bazin-Lee H, St-Jean JR, Larocque D, Baldridge J. Evaluation of novel synthetic TLR7/8 agonists as human vaccine adjuvants. Vaccine. 2016. [Epub ahead of print].
Oberoi, H.; Yorgensen, Y.; Evans, J.; Burkhart, D.; PEG modified liposomes in combination with methylglycol chitosan enhances the murine sublingual immune response to influenza vaccination Journal of Controlled Release, Vol 223, 10 Feb 2016.
Spinner, J.; Oberoi, H.; Yorgensen, Y.; Burkhart, D.; Evans, J.; Methylglycol chitosan and a synthetic TLR4 agonist enhance immune responses to influenza vaccine administered sublingually Vaccine, Volume 33, pages5845-5853, 2015.
Khalaf, W. S. Bowen, H.G. Bazin , K.T. Ryter, M.T. Livesay, J.R. Ward, J.T. Evans, D.A. Johnson, “Characterization of TRIF selectivity in the AGP class of lipid A mimetics: Role of secondary lipid chains”, Bioorg. Med. Chem. Lett., 25, 547-533, 2015
H.G. Bazin, Y. Li, J.K. Khalaf , S. Mwakwari, M.T. Livesay, J.T. Evans, D.A. Johnson, “Structural requirements for TLR7-selective signaling by 9-(4-piperidinylalkyl)-8-oxoadenine derivatives”, Bioorg. Med. Chem. Lett., 25, 1318-1323, 2015
H.G. Bazin, L.S. Bess, M.T. Livesay, D.A. Johnson, “Phospholipidation of TLR7/8-active imidazoquinolines using a tandem phosphoramidite method”, Tetrahedron Lett, 57, 2063-2066, 2016
Mwakwari, L.S. Bess, H.G. Bazin, D.A. Johnson, “Efficient tin-mediated synthesis of lysophospholipid conjugates of a TLR7/8-active imidazoquinoline”, Tetrahedron Lett, 57, 2093-2096, 2016